- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745797
Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy (PCI)
March 2, 2017 updated by: Yi-Long Wu
Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy:A Multi-center Randomized Phase ⅢTrial
- Patients with confirmed advanced NSCLC and any response to 3-6 cycles of chemotherapy, were randomized to receive PCI (30 Gy/10fr) or no PCI.
- The primary endpoint was the cumulative incidence of symptomatic brain metastases (BM) .
- The study was sized to detect a hazard ratio of 0.37 with 80% power and 2-sided 5% significance (60 events, 206 patients).
Study Overview
Detailed Description
- Prophylactic cranial irradiation (PCI) significantly reduces the risk of brain metastases (BM) and improves survival in patients with extensive disease small cell lung cancer after a response to chemotherapy .
- PCI has also demonstrated to reduce or delay the incidence of CNS failure in non small cell lung cancer patients after primary therapy.
- But its impact on overall and disease free survival is uncertain.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Lung Cancer Research Institute & Cancer Center of Guangdong Provincial People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients were required to have histologically or cytologically documented NSCLC and no brain metastasis documented by magnetic resonance imaging (MRI)within 21 days after confirmed response (RR+SD) to chemotherapy
- No previous history of radiotherapy and surgery of brain
- Agree to radiotherapy
- age > 18 and <75 years
- ECOG performance status 1 or less
- Good renal and hepatic and haematological (absolute neutrophils count 15 x1O9/L and platelet count 90 x 109/L,HB>=80g /DL) functions
- Have provided informed consent
Exclusion Criteria:
- Seizure cannot be controled by the drugs
- Combined with other disease of the brain such as tumour or infarction
- Hypersensitivity to MR enhancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prophylactic WBRT
Take the whole brain radiotherapy radiotherapy
|
blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
Other Names:
|
No Intervention: Observer Group
The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint is the cumulative incidence of symptomatic brain metastases (BM) .
Time Frame: 2.5years
|
2.5years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1year survival,overall survival,incidence rate of radioactive brain injured
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: WU YI LONG, MD, Chinese Society of Lung Cancer
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
September 2, 2008
First Submitted That Met QC Criteria
September 2, 2008
First Posted (Estimate)
September 3, 2008
Study Record Updates
Last Update Posted (Actual)
March 6, 2017
Last Update Submitted That Met QC Criteria
March 2, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
Other Study ID Numbers
- CSLC0801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
University of Vermont Medical CenterRecruiting
-
University Hospital, BrestRecruiting
-
Ohio State University Comprehensive Cancer CenterRecruitingBrain Metastases, AdultUnited States
-
Allegheny Singer Research Institute (also known...Elekta LimitedRecruitingBrain Metastases, AdultUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteTerminatedMultiple Brain MetastasesUnited States
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...CompletedBrain Cancer | Neoplasm MetastasesChina
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomUnknown
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
Clinical Trials on Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
IRCCS San RaffaeleRecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, ClinicalItaly
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands
-
Radboud University Medical CenterKoningin Wilhelmina Fonds; Maastro Clinic, The NetherlandsTerminatedSpinal MetastasesNetherlands
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownGastric CancerSingapore
-
Changhai HospitalRecruiting
-
UNC Lineberger Comprehensive Cancer CenterNot yet recruitingHead and Neck Cancer | Xerostomia | Oropharynx CancerUnited States